Sort
51,593 grants matching “hepatitis”
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection
$709,110Raymond T Chung · Massachusetts General Hospital · R01 · FY2025 · AI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection
$709,110Raymond T Chung · Massachusetts General Hospital · R01 · FY2024 · AI
Gut flora metabolism of dietary phosphatidylcholine and cardiovascular disease
$709,072Stanley L Hazen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2014 · HL
Bay Area Hepatitis C Cooperative Research Center
$709,063Joseph M McCune · University Of California, San Francisco · U19 · FY2011 · AI
Insulin and nutrient actions in the FGR fetal liver
$708,887Stephanie R Wesolowski · University Of Colorado Denver · R01 · FY2025 · DK
Integrated eHealth for HIV and Substance Use Disorders in Justice-involved Women
$708,877Jaimie Meyer · Yale University · R01 · FY2023 · DA
Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I
$708,768Raymond Yu Jeang Wang · Children'S Hospital Of Orange County · R01 · FY2023 · HD
Evaluating a Microfinance Intervention for High Risk Women in Kazakhstan
$708,767Nabila El-Bassel · Columbia Univ New York Morningside · R01 · FY2016 · DA
Enhancing immune regulation in gene therapy for hemophilia
$708,753Roland W. Herzog · Indiana University Indianapolis · R01 · FY2018 · HL
High Throughput Assays for Drug Glucuronidation
$708,643Bellbrook Labs, Llc · R44 · FY2002 · GM
NATURAL HISTORY OF HCV INFECTION IN DRUG USERS
$708,625Montefiore Medical Center (Bronx, Ny) · R01 · FY2002 · DA
Mechanisms connecting dysregulated BCAA, glucose & lipid metabolism in the pathogenesis of metabolic disease
$708,592Christopher B Newgard · Duke University · R01 · FY2019 · DK
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs
$708,571David L Thomas · Johns Hopkins University · R01 · FY2020 · DA
The Progression of Hepatitis C Among IDUs with HIV
$708,416David L Thomas · Johns Hopkins University · R01 · FY2013 · DA
Mechanisms of Post-Bariatric Hypoglycemia
$708,315Darleen A Sandoval · University Of Colorado Denver · R01 · FY2021 · DK
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases
$708,166Mark A Kay · Stanford University · R37 · FY2021 · AI
A proteomics atlas of HIV/HBV infections for curing HBV
$708,086Eleftherios Michailidis · Emory University · R01 · FY2025 · AI
The Progression of Hepatitis C Among IDUs
$708,063David L Thomas · Johns Hopkins University · R01 · FY2007 · DA
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
$708,050Harel Dahari · Loyola University Chicago · R01 · FY2023 · AI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases
$708,016Mark A Kay · Stanford University · R37 · FY2022 · AI
A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs
$707,950Meghan D Morris · University Of California, San Francisco · R01 · FY2024 · DA
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B
$707,841Stewart Cooper · California Pacific Med Ctr Res Institute · R01 · FY2018 · DK
Impact of Eliminating Extended Duration Work Shifts on Resident Health and Safety
$707,833Laura K. Barger · Brigham And Women'S Hospital · R01 · FY2014 · OH
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies
$707,682Mandana Khalili · University Of California, San Francisco · U01 · FY2022 · DK
Universal HCV screening in pregnancy: Examining testing uptake and HCV care
$707,647Shashi Kapadia · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · DA